MARKET

EVFM

EVFM

Evofem Bioscienc
OTCMQB
0.074
-0.003
-3.77%
Closed 15:56 11/28 EST
OPEN
0.075
PREV CLOSE
0.074
HIGH
0.080
LOW
0.070
VOLUME
1.08M
TURNOVER
79.91K
52 WEEK HIGH
14.61
52 WEEK LOW
0.070
MARKET CAP
2.62M
P/E (TTM)
-0.0038
1D
5D
1M
3M
1Y
5Y
Georgia Supreme Court Reinstates State's Ban On Abortions After Roughly Six Weeks Of Pregnancy
Benzinga · 5d ago
Abortion Opponents Sue FDA And HHS, Seeking To Reverse Abortion Pill's Approval; Lawsuit Also Seeks To Undo FDA Decisions Easing Access To Mifepristone
Benzinga · 11/18 18:42
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades
Benzinga · 10/13 14:05
Stifel Downgrades Evofem Biosciences to Hold, Lowers Price Target to $0.5
Stifel analyst Annabel Samimy downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold and lowers the price target from $3 to $0.5.
Benzinga · 10/13 09:38
--Stifel Downgrades Evofem Biosciences to Hold From Buy, Adjusts Price Target to $0.50 From $3
--Stifel Downgrades Evofem Biosciences to Hold From Buy, Adjusts Price Target to $0.50 From $3
MT Newswires · 10/13 05:11
Why Evofem Biosciences Shares Are Plunging Today?
Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its endpoints.
Benzinga · 10/12 18:17
Evofem's Phexxi fails in phase 3 trial to prevent chlamydia, gonorrhea in women
Evofem Biosciences (OTCQB:EVFM) <a href="https://seekingalpha.com/pr/18972367-evofem-reports-top-line-re...
Seekingalpha · 10/12 09:55
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.
PR Newswire · 10/12 01:00
More
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

Webull offers kinds of Evofem Biosciences Inc stock information, including OTCMQB:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.